PMID- 21738030
OWN - NLM
STAT- MEDLINE
DCOM- 20111216
LR  - 20131121
IS  - 1473-6543 (Electronic)
IS  - 1062-4821 (Linking)
VI  - 20
IP  - 5
DP  - 2011 Sep
TI  - The role of incretins in salt-sensitive hypertension: the potential use of 
      dipeptidyl peptidase-IV inhibitors.
PG  - 476-81
LID - 10.1097/MNH.0b013e328349af9d [doi]
AB  - PURPOSE OF REVIEW: Incretin mimetics, such as glucagon-like peptide-1 (GLP-1) and 
      glucose-dependent insulinotropic polypeptide (GIP), as well as dipeptidyl 
      peptidase-IV (DPP-IV) inhibitors, are used in the treatment of type 2 diabetes 
      mellitus (T2DM). In addition to stimulating insulin secretion from pancreatic beta 
      cells, incretins have apparent extrapancreatic functions beyond glycemic control. 
      This review summarizes the recent findings regarding the blood-pressure-lowering 
      effects of incretins and DPP-IV inhibitors in patients who are obese, diabetic, 
      or have metabolic syndrome. RECENT FINDINGS: Clinical studies have indicated that 
      GLP-1 and its analogues lower blood pressure in patients with T2DM, particularly 
      in patients with moderate-to-severe hypertension. DPP-IV inhibitors also appear 
      to elicit a similar blood-pressure-lowering effect. In animal models of 
      salt-sensitive hypertension, incretins appear to induce their antihypertensive 
      effects by inhibiting the proximal tubular sodium reabsorption, and thereby 
      increasing urinary excretion of sodium. These data suggest that the local actions 
      of incretins may be via their key role in regulating natriuresis and lowering 
      blood pressure. SUMMARY: Incretin mimetics and DPP-IV inhibitors are a novel 
      class of antihypertensive drugs with natriuretic properties. They can be used in 
      the treatment of salt-sensitive hypertension, which is characterized by edema.
FAU - Tanaka, Tetsuhiro
AU  - Tanaka T
AD  - Division for Health Service Promotion, University of Tokyo, School of Medicine, 
      Tokyo, Japan.
FAU - Nangaku, Masaomi
AU  - Nangaku M
FAU - Nishiyama, Akira
AU  - Nishiyama A
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Curr Opin Nephrol Hypertens
JT  - Current opinion in nephrology and hypertension
JID - 9303753
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Incretins)
RN  - 0 (Sodium Chloride, Dietary)
RN  - 9NEZ333N27 (Sodium)
SB  - IM
MH  - Animals
MH  - Antihypertensive Agents/*therapeutic use
MH  - Blood Pressure/drug effects
MH  - Dipeptidyl-Peptidase IV Inhibitors/*therapeutic use
MH  - Disease Models, Animal
MH  - Humans
MH  - Hypertension/*drug therapy/enzymology/etiology/physiopathology
MH  - Incretins/*therapeutic use
MH  - Kidney Tubules, Proximal/drug effects/metabolism
MH  - Molecular Mimicry
MH  - Natriuresis/drug effects
MH  - Sodium/metabolism
MH  - Sodium Chloride, Dietary/*adverse effects
MH  - Treatment Outcome
EDAT- 2011/07/09 06:00
MHDA- 2011/12/17 06:00
CRDT- 2011/07/09 06:00
PHST- 2011/07/09 06:00 [entrez]
PHST- 2011/07/09 06:00 [pubmed]
PHST- 2011/12/17 06:00 [medline]
AID - 10.1097/MNH.0b013e328349af9d [doi]
PST - ppublish
SO  - Curr Opin Nephrol Hypertens. 2011 Sep;20(5):476-81. doi: 
      10.1097/MNH.0b013e328349af9d.